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Abstract 
Purpose: To evaluate the current prescription pattern and appropriateness of proton pump inhibitors 
(PPIs) in two of the largest tertiary hospitals in Jordan, and also to determine their utilization rate among 
the admitted patients.  
Methods: A retrospective cross-sectional study was conducted over 10 months (February-November 
2013) at two Jordanian tertiary hospitals.  A total of 193 patients, both in intensive care unit (ICU) and 
non-ICU, who were receiving PPIs prescriptions as part of their drug regimen during their 
hospitalization, were recruited. Patients were accessed from different hospitals’ wards (non-ICU and 
ICU) using a convenient sampling technique. The appropriateness of PPIs and the rationale for their 
prescription as a treatment or prevention therapy were evaluated according to the recent treatment 
guidelines. 
Results: The results showed that PPIs were being overused; only 53 patients (27.5 %) were prescribed 
PPIs for a correct indication, while the remaining 140 patients (72.5 %) were receiving PPIs without any 
documented valid indication. By comparing the patients according to their site of care, 52.4 % (43/82) of 
ICU patients compared to 87.4 % (97/111) of medically hospitalized patient (non-ICU) were 
inappropriately receiving PPIs (p = 0.000).    
Conclusion: Adherence to the current practice guidelines for safe prescription of PPIs is poor. Thus, 
updating physicians on the practice guidelines, participation of a clinical pharmacist in making 
therapeutic decisions and modifying hospital formularies are measures that would be helpful and thus 
contribute to improved healthcare in Jordan.  
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Proton pump inhibitors (PPIs) are among the 
most commonly prescribed drugs worldwide [1]. 
They are a class of medications widely used to 
suppress gastric acid secretion; playing a central 
role in the management of different conditions 
such as duodenal and gastric ulcers, severe 
reflux oesophagitis, scleroderma oesophagitis, 
and Zollinger–Ellison syndrome [2,3]. They are 
also prescribed as a prophylactic treatment for 
stress ulcer in intensive care units (ICU) patients 
[4], in preventing gastric ulcers induced by non-
steroidal anti-inflammatory drugs (NSAIDs) [5] 
and combined to antibiotic therapy as part of the 
eradication regimen of Helicobacter pylori in 
patients with peptic ulcer disease [6]. 
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Nowadays, PPIs are considered the most potent 
gastric acid-suppressing agents available in 
clinical use; they are substantially more potent, 
longer-acting than H2-receptor antagonists and 
produce a faster, and more complete healing of 
oesophagitis as well as relieving of heartburn [7-
9].  
 
Although extensive clinical trials and post-
marketing surveillance indicate that PPIs are 
safe and well tolerated, their use has been linked 
to a broad spectrum of adverse events affecting 
different body systems, such as increased risk of 
intestinal dysbiosis, specific infections, including 
pneumonia and Clostridium difficile infection, 
osteoporosis, nutritional deficiencies [10-12]. In 
addition, the cost of PPIs exceeds that of any 
other acid inhibiting medication and the volume 
of prescribing them has had a substantial impact 
on the medical bills worldwide [13,14]. In this 
regard, several reports have suggested that PPIs 
are being overused in hospital and ambulatory 
care settings [10,15,16], and that the 
appropriateness of PPIs prescriptions in some 
hospitals may be as low as 8.3 % [16]. 
Suggested causes contributing to the 
inappropriate overuse of PPIs include physician 
type, practice setting, formulary status and 
consumer-oriented advertising [17]. 
 
Based on this, the concept of overuse of these 
acid-inhibiting agents in the clinical practice has 
received significant attention; relative to both the 
potential for adverse effects and the preventable 
cost-expenditure. Indeed, studies spanning over 
a decade have demonstrated that physicians, in 
both primary and specialty care, may 
overprescribe these medications without re-
evaluating patients for persistent clinical 
indication [10,15,16]. Thus, the main aim of this 
current study was to evaluate the current 
prescription status of PPIs in medical patients, 
this will help to establish a policy to ensure 
appropriate therapy prescription and minimizing 




Study design, settings, and data collection 
 
A retrospective cross-sectional study was carried 
out on patients treated at two of the busiest 
tertiary hospitals (Jordan university hospital and 
Jordan hospital) in Amman between February-
November 2013. During the study period, 200 
adult patients, who fulfilled the inclusion criteria, 
were approached, out of which 193 patients 
agreed to take part in the study (response rate 
96.5 %). The inclusion criteria included adult 
patients (≥ 18 years of age) who were receiving 
any PPIs as part of their drug regimen started 
during their hospitalization. Patients were 
accessed from different hospitals’ wards (non-
ICU and ICU) using convenient sampling 
technique. 
 
Well-trained assistants, using a structured 
questionnaire, recruited the study sample. 
Information regarding demographic data, clinical 
characteristics, medical history, current 
medications, and risk for peptic ulcer disease i.e. 
use of NSAID, and stress-induced ulcer were 
collected and documented. Data were collected 





The study was conducted following the ethical 
standards outlined in the World Medical 
Association Declaration of Helsinki guidelines 
[18]. All participants were required to provide a 
written informed consent. Ethical approval was 
obtained from both the University of Jordan (ref 
no. 1/23/2015/2016) and Jordan Hospital (ref no. 
15/1/2013). 
 
Determination of appropriateness of PPIs 
prescription 
 
The appropriateness of PPIs and the rationale 
behind their prescription as a therapeutic and 
prophylactic agent were evaluated according to 
latest guidelines (Table 1) [3-6]. Accordingly, 
patients were classified into four categories: 1) 
those receiving PPIs as a treatment for gastric-
acid related disorders; 2) those receiving PPIs for 
prevention against stress-induced ulcer; 3) those 
receiving PPIs for prevention against NSAIDs-
induced ulcer; and 4) those receiving PPIs for no 
clear therapeutic indication. 
 
To assess NSAIDs-induced ulcer risk, both the 
cardiovascular and gastrointestinal risks were 
evaluated [5]. Except for those at low 
cardiovascular and low gastrointestinal risk, all 
patients on NSAIDs require the addition of PPI 
therapy. Risk for stress-induced ulcer was 
assessed by evaluating the presence of majors 
and minors risk factors, if any patient has at least 
one major or two minor risk factors, then PPIs 




All data were entered and analyzed using 
SPSS© 19 (SPSS, Inc., Chicago, IL, USA).  
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Table 1:  Therapeutics indications for PPIs according to regulatory agencies 
 
Indications         Subcategories 
Indication for PPIs as a treatment [3, 
6] 
1. H. Pylori eradication regimen. 
2. Active gastric ulcer or duodenal ulcer disease. 
3. GERD. 
4. Patients with Zollinger-Ellison syndrome. 
5. Suspected upper gastrointestinal bleeding. 
6. Patients with uninvestigated dyspepsia may be given full dose PPIs 
for one month to assess response. 
7. Maintenance treatment of erosive esophagitis 
8. Chest pain with negative cardiac and pulmonary work up that is 
suspected to be due to dyspepsia or gastroesophageal reflux 
disease. 
Risk factors for stress induced ulcer 
in ICU patients (at least one major or 
two minor risk factors are needed) [4] 
     Major risk factors 
1. Coagulopathy, defined as a platelet count < 50,000 per m3, an 
International Normalized Ratio (INR) > 1.5, or a partial 
thromboplastin time (PTT) > 2 times the control value. 
2. Mechanical ventilation for more than 48 hours. 
3. History of GI ulceration or bleeding with the past year. 
4. Traumatic brain injury, traumatic spinal cord injury, or burn injury ( > 
35 percent of the body surface area). 
      Minor risk factors 
1. Sepsis 
2. ICU admission lasting > 1 week 
3. Occult GI bleeding lasting ≥ 6 days 
4. Glucocorticoid therapy. 
Risk factors for NSAIDs induced 
ulcer [5] 
All patients require PPIs except those with low gastrointestinal and low 
cardiovascular risk 
 
Categorical variables were expressed as 
frequencies and percentages, while continuous 
variables were presented as means ± standard 
deviation (SD). Normality of the data was 
determined using the different normality 
indicators (skewness and kurtosis). Chi- Square 
test was used to evaluate difference between 
groups for categorical variables. For all statistical 
analysis, p < 0.05 was considered statistically 




The demographic details of patients included in 
this study are presented in Table 2. The mean 
age was 62.8 years and around 42.5 % (82 
patients) of patients were ICU patients. Women 
accounted for 54.4 % (105 patients) of all the 
patients recruited. At present, there are five PPIs 
available in Jordan: omeprazole, lansoprazole, 
pantoprazole, rebeprazole and esomeprazole. 
Lansoprazole was the most commonly 
prescribed PPIs (112 patients, 58.0 %), followed 
by omeprazole (64 patients, 33.2 %) and 
esomeprazole (17 patients, 8.8 %). Pantoprazole 
and rebeprazole were not prescribed at all. 
 
The appropriateness of PPIs prescription among 
study sample was assessed by taking into 
account the indications and risk factors 
mentioned previously in Table 1. Table 3 showed 
that only 27.5 % of patients (53 patients) have 
received a proton pump inhibitor for valid 
indications. When stratifying patients according 
to their site of care, 52.4 % (43/82) of ICU 
patients compared to 87.4 % (97/111) of 
medically hospitalized patient (non-ICU) were 
found to receive PPIs for no valid medical 
indication (p = 0.000). 
 
Among patients with valid indications, 21 patients 
(10.9 %) have approved gastric acid disorders, 
29 patients (15.0 %) were at risk for stress-
induced ulcer, while only 3 patients (1.6 %) were 
at risk for NSAIDs induced ulcer. It is obvious 
that mechanical ventilation for more than 48 
hours was the most common risk factor 
encountered (18 patients, 9.3 %). 
 
On the other hand, when looking at the patients 
on PPIs with no clear indications, investigation of 
reasons behind inappropriateness of PPIs 
prescriptions showed that 51 patients (36.4 %) 
were on PPIs because they were concomitantly 
receiving low dose of aspirin without other risk 
factors for gastrointestinal tract bleeding. Other 
subsequent reasons behind inappropriate PPI 
use were; use of corticosteroids (20 patients, 
14.3 %), use of low molecular weight heparin (30 
patients, 21.4 %); use of warfarin (7 patients, 5.0 
%), and use of unfractionated heparin (4 
patients, 2.9 %). Regarding the remaining 28 
patients (20.0 %), there were no documented 
indications reported in patients’ medical records. 
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Table 2: Demographic characteristics of the study sample (N = 193) 
 
Parameter  N (%) 




















































Table 3: Distribution of patients based on their PPIs’ indications (N = 193) 
 
Indication  N (%) 
Approved gastric acid disorders for a prescribed PPIs (21 patients) 
H. Pylori eradication regimen. 2 (1.0) 
Active gastric ulcer or duodenal ulcer disease confirmed at endoscopy. 4 (2.1) 
GERD confirmed at endoscopy. 6 (3.1) 
Suspected upper gastrointestinal bleeding. 3 (1.6) 
Patients with uninvestigated dyspepsia may be given full dose PPIs for one month to 
assess response. 
5 (2.6) 
Maintenance treatment of erosive esophagitis 1 (0.5) 
 
Stress induced ulcer with one major risk factors  (26 patients) 
Coagulopathy, defined as a platelet count < 50,000 per m3, an International Normalized 
Ratio (INR) > 1.5, or a partial thromboplastin time (PTT) > 2 times the control value. 
2 (1.0) 
Mechanical ventilation for more than 48 hours. 18 (9.3) 
History of GI ulceration or bleeding with the past year. 5 (2.6) 
Traumatic brain injury, traumatic spinal cord injury, or burn injury ( > 35 percent of the 
body surface area). 
1 (0.5) 
 




NSAID induced peptic ulcer (3 patients) 3 (1.6) 
 




PPIs comprise a cornerstone in the management 
of a vast plethora of gastric acid associated 
conditions. Although they are considered a safe 
and effective group of pharmaceutical agents, 
their use is not void of serious adverse events 
[10-12]. Using PPIs safely requires striking the 
current guidelines and recommendations issued 
by regulatory agencies [3-6]. As recommended 
by recent guidelines, PPIs are prescribed only for 
patients with approved gastric acid disorders as 
well as for prevention of stress and NSAIDs 
induced ulcer. Unfortunately, there is a growing 
body of evidence that there is a dramatic 
increase in PPIs overuse in hospital and 
ambulatory care settings that is associated with 
certain health hazards, and lead to an 
unnecessary waste of hospital resources as well 
as overall health system resources [10,15,16]. 
Whether guidelines recommendations are being 
followed or implemented in clinical practice was 
generally unknown in Jordan. 
 
Lansoprazole was the most commonly 
prescribed PPIs among study patients. Despite 
the fact that all PPIs are equally effective at 
appropriate recommended doses, pantoprazole 
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and lansoprazole appear to have a less 
significant potential to provoke any significant 
drug-drug interactions if compared to 
esomeprazole or omeprazole [19]. Identification 
of the most commonly prescribed PPIs was 
selected to determine points of strengths in the 
current health care system in Jordan. Since the 
majority of study participants were on multi drug 
regimen, it is possible that prescribing physicians 
took into consideration to use the least PPIs to 
provoke drug- drug interaction. This may reflect a 
good practice by physician to protect their 
patients from any possible harmful interactions 
between medications. 
 
This study showed that 72.5 % of participants 
examined did not follow current guidelines or 
recommendations for PPIs prescriptions. By 
comparing patients according to their site of care, 
the inappropriateness of PPIs prescription was 
much higher in non-ICU patient compared to ICU 
patients (87.4 % versus 52.4 %, respectively). 
Several previous studies reached a similar 
conclusion and have shown that there was an 
overuse of PPIs in different clinical settings 
[10,15,20-22]. Two studies conducted in a major 
teaching hospital in Tasmania and United 
kingdom, showed that inappropriate prescription 
of PPIs were around 60.4 %  and 56.0 %, 
respectively [10,20]. A similar study, conducted 
to assess the appropriateness of PPIs 
prescription in patients with chronic renal failure 
and compared them with hospitalized patients 
and patients with other chronic diseases, 
revealed a high inadequate use of acid 
suppressive therapy in chronic renal failure 
patients (63 %) as well as hospitalized patients 
(81 %) compared to those with another chronic 
disease (32 %) [22]. More recently, it was 
demonstrated that 61 % of patients admitted to 
four different hospitals in the state of Maryland 
received PPIs improperly [15]. In Mexico, the 
prescription of PPIs was inappropriate in just 
35.5 % of the cases [21]. 
 
The use aspirin or corticosteroid therapies was 
found among the most critical areas where PPIs 
were overused. For patients who required low 
dose aspirin for either primary or secondary 
prevention of cardiovascular events, both the 
additional risk and cost make the inclusion of 
PPIs unwarranted and thus inappropriate [23]. 
Also it is obvious from these data that physicians 
are still convinced in the myth of steroid ulcer, 
which is consistent with the result of a recent 
survey that showed that 82 % of physicians 
believe that corticosteroids are ulcerogenic [24]. 
However, it has been documented that the 
incidence of ulcer in patients receiving 
corticosteroids is very low. Thus, the concomitant 
use of anti-secretory medications is not 
necessary with the exception of the patients on 
long-term, high-dose steroids or patients on 
concomitant non-steroid anti-inflammatory drugs 
[25]. 
 
The results obtained from this study, which was 
conducted for the first time in Jordan, clearly 
demonstrate that PPIs are over-prescribed in 
medically hospitalized and ICU patients. This 
represents a major flaw in PPIs management 
protocols in Jordan. Sadly, the same issues that 
were found pertaining the PPIs therapies might 
be applied to other classes of pharmacologic 
agents and other hospitals in Jordan. Even 
though, additional studies are needed to better 
evaluate the prescription behavior of these 
potent acid-suppressing agents in clinical 
practice. In this regard, several issues have 
arisen that deserve further investigations. In 
particular, the following remain to be assessed: 
1) the number of patients prescribed PPIs in 
relation to the total number of patients admitted 
to the hospital; and 2) the reasons of 
inappropriate PPIs prescriptions in patients with 
no clear indications in their medical files.  
 
Limitations of the study 
 
This study has a number of methodological 
limitations, including the retrospective nature of 
the survey. In addition, study data were collected 
only in two hospitals, and hence a multi-centered 
investigation may be needed to obtain results 
that could better reflect the prescription patterns 
in Jordan. It is also possible that documentation 
of indications for PPIs use in some medical 
records was not comprehensive enough in this 
study, which may result in overestimation of the 




The current study is the first in Jordan to 
evaluate the prescription patterns and 
appropriateness of PPI therapies. The findings 
provide valuable information on the over-
prescription of PPIs therapies in Jordan. The 
findings show that adherence to guidelines for 
safe prescription of PPIs was poor, and therefore 
afford a basis to establish strategies for 
medication management system that will improve 
clinical outcomes in patients on PPIs therapies. 
One of these strategies could be the use of a 
well-designed protocol that contains all the 
proper indications for PPIs prescribing. In 
addition, updating physicians’ awareness and 
knowledge on the appropriate indications for 
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PPIs requires urgent attention in order to improve 
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